13F Holdings
中文EN

GRAL GRAIL, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1699031 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY0.0%
TTM EPS YoY13.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-347.3%
Net margin-243.8%
FCF margin-187.3%
EBITDA margin-337.4%

Returns

ROE-17.3%
ROA-15.2%
ROIC (approx.)-20.1%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio8.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue3.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20232023-01-01
Income statement
Revenue$147.17M$125.59M$93.11M$55.55M
R&D expense$195.79M$322.38M$338.75M$329.58M
SG&A expense$159.10M$213.86M$200.27M$174.11M
Operating income-$562.16M-$2.19B-$1.52B-$5.44B
Pretax income-$534.50M-$2.16B-$1.51B-$5.44B
Income tax-$126.15M-$135.36M-$41.95M-$42.29M
Net income-$408.35M-$2.03B-$1.47B-$5.40B
EBITDA-$544.15M-$2.17B-$1.50B-$5.43B
EPS (basic)-11.11-63.54-47.21-173.89
EPS (diluted)-11.11-63.54-47.21-173.89
Weighted avg. shares (diluted)36.75M31.90M31.05M31.05M
Balance sheet
Cash & equivalents$249.73M$217.58M$97.29M$241.60M
Receivables$18.30M$20.31M$16.94M—
Current assets$953.85M$819.86M$156.06M—
PP&E, net$51.81M$69.06M$85.00M—
Goodwill—$0$888.94M$1.50B
Intangibles$1.85B$2.02B$2.69B—
Total assets$2.92B$2.98B$3.91B—
Current liabilities$79.67M$76.92M$163.61M—
Total liabilities$344.15M$479.90M$267.63M—
Shareholders' equity$2.58B$2.50B——
Shares outstanding40.33M33.89M0—
Cash flow statement
Operating cash flow-$299.01M-$577.16M-$595.80M-$561.31M
Capital expenditure$909,000$5.21M$12.89M$22.86M
Free cash flow-$299.92M-$582.36M-$608.69M-$584.17M
Investing cash flow-$85.05M-$551.01M-$12.89M-$22.86M
Financing cash flow$423.32M$1.24B$463.77M$604.82M
Depreciation & amortization$18.01M$19.72M$20.36M$16.43M
Stock-based compensation$58.28M$86.08M$97.23M$75.73M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.